[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cardiovascular-disorders\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cardiovascular-disorders":27},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,2,0,[8,53],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":4,"briefSummary":22,"conditions":23,"keywords":4,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":41,"lastUpdatePostDateStruct":42,"startDateStruct":45,"completionDateStruct":47,"leadSponsor":49,"locationsCount":52},"100172884","product-surveillance-registry-100172884",false,"NCT01524276","Product Surveillance Registry","Medtronic Product Surveillance Registry","PSR","Inclusion Criteria:\n\n* Patient or legally authorized representative provides written authorization and\u002For consent per institution and geographical requirements\n* Patient has or is intended to receive or be treated with an eligible Medtronic product\n* Patient within enrollment window relative to therapy initiation or meets criteria for retrospective enrollment\n\nExclusion Criteria:\n\n* Patient who is, or will be, inaccessible for follow-up\n* Patient with exclusion criteria required by local law\n* Patient is currently enrolled in or plans to enroll in any concurrent drug and\u002For device study that may confound results","ALL",{"count":19,"type":20},100000,"ESTIMATED","OBSERVATIONAL","The purpose of the Registry is to provide continuing evaluation and periodic reporting of safety and effectiveness of Medtronic market-released products. The Registry data is intended to benefit and support interests of patients, hospitals, clinicians, regulatory bodies, payers, and industry by streamlining the clinical surveillance process and facilitating leading edge performance assessment via the least burdensome approach.",[24,25,26,27,28,29,30,31,32,33,34,35,36,37,38,39],"Cardiac Rhythm Disorders","Urological Disorders","Neurological Disorders","Cardiovascular Disorders","Digestive Disorders","Intracranial Aneurysm","Mechanical Circulatory Support","Respiratory Therapy","Aortic, Peripheral Vascular and Venous Disorders","Minimally Invasive Surgical Procedures","Diagnostic Techniques and Procedures","Surgical Procedures, Operative","Renal Insufficiency","Neurovascular","Coronary Artery Disease","Ear, Nose and Throat Disorder","RECRUITING","2026-06-15",{"date":43,"type":44},"2026-06-17","ACTUAL",{"date":46,"type":4},"2012-01",{"date":48,"type":20},"2040-01",{"name":50,"class":51},"Medtronic","INDUSTRY",395,{"id":54,"slug":55,"hasResults":11,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":4,"eligibilityCriteria":59,"healthyVolunteers":60,"sex":17,"minAge":61,"maxAge":4,"enrollmentInfo":62,"targetDuration":4,"studyType":64,"phases":65,"briefSummary":68,"conditions":69,"keywords":80,"overallStatus":40,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":117},"100415052","phase-1-mesenchymal-stem-cells-for-the-treatment-of-various-chronic-and-acute-conditions-100415052","NCT04684602","Mesenchymal Stem Cells for the Treatment of Various Chronic and Acute Conditions","Evaluation of the Safety, Tolerability and Efficacy of Regenerative Therapy for the Treatment of Various Chronic and Acute Conditions","Inclusion Criteria:\n\n* Age 18 and older\n* Ability to provide informed consent\n* Availability for follow up visits\n\nExclusion Criteria:\n\n* Active or recent malignancy (within last 2 years)\n* Pregnancy or breast-feeding\n* Inability to provide informed consent",true,"18 Years",{"count":63,"type":20},5000,"INTERVENTIONAL",[66,67],"PHASE1","PHASE2","This multi-arm, multi-site study investigates the safety, tolerability, and efficacy of stem cell therapy for the treatment of various acute and chronic conditions. Clinically observed initial findings and an extensive body of research indicate regenerative treatments are both safe and effective for the treatment of multiple conditions.",[70,27,71,72,73,74,75,76,77,78,79],"Autoimmune Diseases","Diabetes Complications","Integumentary Disease","Musculoskeletal Disorders","Neurodegenerative Disorders","Neurologic Disorders","Pulmonary Disorders","Sexual Dysfunction","Urologic Disorders","Viral Illness",[81,82,83,84,85,86,87,88,89,90,91,92,93,94,95,96,97,98,99,100,101,102,103,104,105,106,107],"stem cell therapy","umbilical cord stem cells","amniotic stem cells","stem cells","MSC","Mesenchymal Stem Cell","Medicinal Signaling Cell","Erectile Dysfunction","Heart Diseases","Mental Disorders","Neurocognitive Disorders","Neurodegenerative Diseases","Central Nervous System Diseases","Tauopathies","Brain Diseases","Dementia","Disease","Cardiomyopathies","Urologic Diseases","Peripheral Nervous System Diseases","Nervous System Diseases","Alzheimer Disease","Musculoskeletal Diseases","Cardiovascular Diseases","Immune System Diseases","Neuromuscular Diseases","Covid-19","2022-04-27",{"date":110,"type":44},"2022-04-29",{"date":112,"type":44},"2020-07-09",{"date":114,"type":20},"2030-12-09",{"name":116,"class":51},"Thomas Advanced Medical LLC",1]